Known targets — ChEMBL curated mechanism
POLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PRIM1PRIM2RRM1RRM2RRM2B
The experimentally established mechanism targets of Gemcitabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 known ✓ | P09884 | 2/20 | 0.61 |
| ▸ | PDE3A | Q14432 | 3/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.60 |
| ▸ | MTOR | P42345 | 1/20 | 0.60 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.60 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.60 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.60 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.49 |
| ▸ | ALB | P02768 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.49 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.49 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.49 |
| ▸ | CDA | P32320 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gemcitabine SCHEMBL19235640 | 1.00 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL6369622 | 1.00 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL13262185 | 1.00 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL12737233 | 1.00 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL19526092 | 1.00 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL6761683 | 1.00 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL17858716 | 1.00 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL12503065 | 1.00 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL249738 | 1.00 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL20827751 | 1.00 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 199656 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2026-05-28 | — | — | US | claimed |
| US-20260144817-A1 | INTRAVESICAL TIL THERAPY IN BCG-EXPOSED PATIENTS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2026-05-28 | — | — | US | claimed |
| US-20260144809-A1 | METHODS OF TREATING BACILLUS CALMETTE-GUÉRIN (BCG)-NAÏVE HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER (HR-NMIBC) | TARIS BIOMEDICAL LLC (US) | 2026-05-28 | — | — | US | claimed |
| EP-4747388-A1 | RECOMBINANT BACTERIAL CELL CAPABLE OF EXPRESSING A HETEROLOGOUS EXTRACELLULAR MATRIX (ECM) DEGRADING POLYPEPTIDE USING A TUMOUR-INDUCIBLE PROMOTER | NEOBE THERAPEUTICS LTD (GB) | 2026-05-27 | — | — | EP | claimed |
| EP-4747408-A1 | DIAGNOSTIC AND THERAPEUTIC METHODS FOR CANCER | GENENTECH, INC. (US) | 2026-05-27 | — | — | EP | claimed |
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| EP-4746876-A1 | UDP-GLUCOSE CERAMIDE GLUCOSYLTRANSFERASE SYNTHASE (UGCG) INHIBITORS IN THE TREATMENT OF CANCER | Katholieke Universiteit Leuven (BE) | 2026-05-27 | — | — | EP | claimed |
| EP-4011871-B1 | PROCESSES FOR PREPARING OXATHIAZIN-LIKE COMPOUNDS | PERSEVERE THERAPEUTICS INC (US) | 2026-05-27 | — | — | EP | claimed |
| EP-4746850-A1 | EXTENDED RELEASE DRUG-LOADED MICROPARTICLES | Ferring BV (NL) | 2026-05-27 | — | — | EP | claimed |
| CN-122080142-A | Polypeptide for cancer targeted therapy and corresponding drug/fluorescent dye conjugate thereof | — | 2026-05-26 | — | — | CN | claimed |
| WO-1998000159-A1 | USEFUL FORMULATIONS OF ACID ADDITION SALT DRUGS | OXIGENE, INC. (US) | 1998-01-08 | — | — | WO | claimed |
| WO-1997040835-A1 | TREATMENT OF CARCINOMAS USING SQUALAMINE IN COMBINATION WITH OTHER ANTI-CANCER AGENTS | MAGAININ PHARMACEUTICALS INC. (US) | 1997-11-06 | — | — | WO | claimed |
| US-5612474-A | ANTIBODIES AND IMMUNOLOGY | ELI LILLY AND COMPANY (US) | 1997-03-18 | — | — | US | claimed |
| EP-0750910-A1 | LIPOSOME PREPARATION | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1997-01-02 | — | — | EP | claimed |
| EP-0630905-A1 | Process for selectively isolating bêta-2'-deoxy-2',2'-difluorocytidine or its salts | ELI LILLY AND COMPANY (US) | 1994-12-28 | — | — | EP | claimed |
| US-5223608-A | Process for and intermediates of 2',2'-difluoronucleosides | ELI LILLY AND COMPANY (US) | 1993-06-29 | — | — | US | claimed |
| EP-0376518-A1 | Phospholipid nucleosides | ELI LILLY AND COMPANY (US) | 1990-07-04 | — | — | EP | claimed |
| EP-0345751-A1 | Anti-retroviral diflourinated nucleosides | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-12-13 | — | — | EP | claimed |
| EP-0306190-A2 | Improvements in or relating to 2',2'-difluoronucleosides | ELI LILLY AND COMPANY (US) | 1989-03-08 | — | — | EP | claimed |
| EP-0211354-A2 | Nucleosides and their use as antineoplastic agents | MERRELL DOW PHARMACEUTICALS INC. (US) | 1987-02-25 | — | — | EP | claimed |